{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:15Z","timestamp":1792979895508,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["63-021"],"award-info":[{"award-number":["63-021"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["64-204"],"award-info":[{"award-number":["64-204"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["63-020"],"award-info":[{"award-number":["63-020"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["65-030"],"award-info":[{"award-number":["65-030"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","award":["63-106"],"award-info":[{"award-number":["63-106"]}],"id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ratchadapiseksompotch Fund"},{"DOI":"10.13039\/501100020971","name":"Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF19\/63"],"award-info":[{"award-number":["RA-MF19\/63"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF05\/64"],"award-info":[{"award-number":["RA-MF05\/64"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF35\/65"],"award-info":[{"award-number":["RA-MF35\/65"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF06\/64"],"award-info":[{"award-number":["RA-MF06\/64"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF10\/66"],"award-info":[{"award-number":["RA-MF10\/66"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["RA-MF36\/64"],"award-info":[{"award-number":["RA-MF36\/64"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","award":["T001\/2562"],"award-info":[{"award-number":["T001\/2562"]}],"id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ratchadapiseksompotch Fund"},{"name":"Ratchadapiseksompotch Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The N-Acetyltransferase (NAT2) slow acetylator phenotype has been associated with a higher risk of isoniazid (INH)-induced hepatotoxicity. We investigated the association between NAT2 genotypes with inferred acetylator status, hepatotoxicity, and INH pharmacokinetics in Thai people living with HIV (PLWH) receiving INH-based Tuberculosis (TB) preventive or treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cohort study of Thai PLWH initiating INH-based regimens; NAT2 genotyping classified participants as slow (SA), intermediate (IA), or rapid acetylators (RA). Hepatotoxicity was defined as transaminase elevations more than 2.5 times the upper limit of normal (ULN). Multivariable logistic regression identified genotypes and factors associated with hepatotoxicity. A pharmacokinetic (PK) substudy assessed INH exposure across phenotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 894 participants, 32.4% were SA, 41.2% IA, and 26.4% RA. Hepatotoxicity occurred in 10.9% overall and was highest in SA (15.2%). SA had increased hepatotoxicity risk versus RA (adjusted odds ratio [aOR] 2.43; 95% CI: 1.32\u20134.48). Genotypes NAT2*6A\/*6A (aOR 1.84) and NAT2*7B\/*7B (aOR 4.46) were associated with increased risk; NAT2*4\/*4 was protective (aOR 0.33). Other independent risk factors included high baseline alanine aminotransferase (ALT), HCV co-infection, 2HRZE\/4HR regimen (vs 1HP), and efavirenz-based antiviral therapy (vs dolutegravir). In the PK substudy (n = 93), INH exposure assessed by the area under the concentration time curve from 0 to 24\u2005h, was significantly increased by approximately 2-fold in SA, regardless of anti-TB regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NAT2 SA phenotype, particularly *6A\/*6A and *7B\/*7B genotypes, is associated with an increased risk of anti-tuberculosis-induced hepatotoxicity and higher INH exposure in Thai PLWH. Incorporating NAT2-guided dosing may enhance safety of INH-containing regimens in PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiaf511","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:22:54Z","timestamp":1759234974000},"page":"287-297","source":"Crossref","is-referenced-by-count":4,"title":["<i>NAT<\/i>\n                    2 Polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living With HIV: Insights From a Pharmacogenetic\u2013Pharmacokinetic Cohort Study"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4292-1797","authenticated-orcid":false,"given":"Napon","family":"Hiranburana","sequence":"first","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratchaya","family":"Sophonphan","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-4525","authenticated-orcid":false,"given":"Stephen J","family":"Kerr","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Research Affairs, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"The Kirby Institute, University of New South Wales , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasiwimol","family":"Ubolyam","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warat","family":"Usawakidwiree","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6339","authenticated-orcid":false,"given":"Pattama","family":"Torvorapanit","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital , Bangkok ,","place":["Thailand"]},{"name":"Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gompol","family":"Suwanpimolkul","sequence":"additional","affiliation":[{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital , Bangkok ,","place":["Thailand"]},{"name":"Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7254-6512","authenticated-orcid":false,"given":"Weeraya","family":"Phaisal","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Pharmacogenomics Laboratory, Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-6020","authenticated-orcid":false,"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[{"name":"Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Pharmacogenomics Laboratory, Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]},{"name":"Department of Pharmacology, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-1123","authenticated-orcid":false,"given":"Yong-Soon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine , Busan ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-850X","authenticated-orcid":false,"given":"Jae-Gook","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Pharmacogenomics Research Center, Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine , Busan ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surakameth","family":"Mahasirimongkol","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine and Innovation Support, Department of Medical Sciences, Genomic Medicine Centre, Ministry of Public Health , Nonthaburi ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9611","authenticated-orcid":false,"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2026031304525032200_jiaf511-B1","author":"World Health Organization"},{"key":"2026031304525032200_jiaf511-B2","volume-title":"Thailand Operational plan to end tuberculosis, phase 2 (2023\u20132027)","author":"Ministry of Public Health, Thailand","year":"2023.","edition":"1st ed"},{"key":"2026031304525032200_jiaf511-B3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMra2308181","article-title":"HIV-Associated Tuberculosis","volume":"391","author":"Meintjes","year":"2024","journal-title":"N Engl J Med"},{"key":"2026031304525032200_jiaf511-B4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2026031304525032200_jiaf511-B5","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/bcp.12885","article-title":"Mechanism of isoniazid-induced hepatotoxicity: then and now","volume":"81","author":"Metushi","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2026031304525032200_jiaf511-B6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":"Genetic polymorphism in N-Acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity","volume":"12","author":"Walker","year":"2009","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"2026031304525032200_jiaf511-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.3.1.1","article-title":"Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury","volume":"3","author":"Huang","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026031304525032200_jiaf511-B8","doi-asserted-by":"crossref","first-page":"e13795","DOI":"10.1111\/cts.13795","article-title":"Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: a systematic review","volume":"17","author":"Surarak","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2026031304525032200_jiaf511-B9","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1038\/s41598-023-38716-3","article-title":"Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in Ethiopian tuberculosis patients","volume":"13","author":"Sileshi","year":"2023","journal-title":"Sci Rep"},{"key":"2026031304525032200_jiaf511-B10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/ijmr.IJMR_2013_15","article-title":"N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis","volume":"145","author":"Hemanth Kumar","year":"2017","journal-title":"Indian J Med Res"},{"key":"2026031304525032200_jiaf511-B11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jcph.1931","article-title":"Isoniazid population pharmacokinetics and dose recommendation for Korean patients with Tuberculosis based on target attainment analysis","volume":"61","author":"Cho","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2026031304525032200_jiaf511-B12","first-page":"803","article-title":"Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients","volume":"25","author":"Sotsuka","year":"2011","journal-title":"In Vivo"},{"key":"2026031304525032200_jiaf511-B13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41439-020-0101-7","article-title":"Haplotype-specific PCR for NAT2 diplotyping","volume":"7","author":"Wichukchinda","year":"2020","journal-title":"Human Genome Variation"},{"key":"2026031304525032200_jiaf511-B14","first-page":"547","article-title":"HIV and liver disease: a comprehensive update","volume":"30","author":"Sherman","year":"2022","journal-title":"Top Antivir Med"},{"key":"2026031304525032200_jiaf511-B15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/QAI.0000000000001641","article-title":"Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial","volume":"78","author":"Ngongondo","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026031304525032200_jiaf511-B16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fern\u00e1ndez-Villar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026031304525032200_jiaf511-B17","volume-title":"National Tuberculosis control programme guideline, Thailand 2021","author":"Department of Disease Control","year":"2021"},{"key":"2026031304525032200_jiaf511-B18","author":"Democritus University of Thrace, Department of Molecular Biology and Genetics"},{"key":"2026031304525032200_jiaf511-B19","author":"Pharmacogene Variation Consortium"},{"key":"2026031304525032200_jiaf511-B20","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/jac\/dku210","article-title":"Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study","volume":"69","author":"Prahl","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026031304525032200_jiaf511-B21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"2026031304525032200_jiaf511-B22","first-page":"6003","article-title":"NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis","volume":"13","author":"Higuchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2026031304525032200_jiaf511-B23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1681.2012.05713.x","article-title":"NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients","volume":"39","author":"An","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026031304525032200_jiaf511-B24","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FPC.0000000000000339","article-title":"NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis","volume":"28","author":"Suvichapanich","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"2026031304525032200_jiaf511-B25","doi-asserted-by":"crossref","first-page":"e44629","DOI":"10.1371\/journal.pone.0044629","article-title":"The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype","volume":"7","author":"Ruiz","year":"2012","journal-title":"PLoS One"},{"key":"2026031304525032200_jiaf511-B26","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2026031304525032200_jiaf511-B27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13104-019-4872-1","article-title":"Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia","volume":"13","author":"Zeleke","year":"2020","journal-title":"BMC Res Notes"},{"key":"2026031304525032200_jiaf511-B28","doi-asserted-by":"crossref","first-page":"e64622","DOI":"10.1371\/journal.pone.0064622","article-title":"Anti-Tuberculosis drug induced hepatotoxicity among TB\/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study","volume":"8","author":"Hassen Ali","year":"2013","journal-title":"PLoS One"},{"key":"2026031304525032200_jiaf511-B29","doi-asserted-by":"crossref","first-page":"100422","DOI":"10.1016\/j.lansea.2024.100422","article-title":"The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India","volume":"31","author":"Bhargava","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"2026031304525032200_jiaf511-B30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026031304525032200_jiaf511-B31","first-page":"1072","article-title":"Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin","volume":"133","author":"Sarma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"2026031304525032200_jiaf511-B32","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/cid\/civ155","article-title":"Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study","volume":"60","author":"Luetkemeyer","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026031304525032200_jiaf511-B33","doi-asserted-by":"crossref","first-page":"e83892","DOI":"10.1371\/journal.pone.0083892","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","volume":"8","author":"Lomtadze","year":"2013","journal-title":"PLoS One"},{"key":"2026031304525032200_jiaf511-B34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4254\/wjh.v5.i10.528","article-title":"Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations","volume":"5","author":"Zampino","year":"2013","journal-title":"World J Hepatol"},{"key":"2026031304525032200_jiaf511-B35","doi-asserted-by":"crossref","first-page":"8266878","DOI":"10.1155\/2022\/8266878","article-title":"Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis","volume":"2022","author":"Wang","year":"2022","journal-title":"J Trop Med"},{"key":"2026031304525032200_jiaf511-B36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026031304525032200_jiaf511-B37","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1164\/rccm.202309-1583OC","article-title":"A nanopore sequencing-based pharmacogenomic panel to personalize Tuberculosis drug dosing","volume":"209","author":"Verma","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf511\/64472814\/jiaf511.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/287\/64472814\/jiaf511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/2\/287\/64472814\/jiaf511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:54:39Z","timestamp":1773392079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/2\/287\/8271031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf511","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,10,1]]}}}